Dorsey & Whitney Trust CO LLC Has $311,000 Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Dorsey & Whitney Trust CO LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,409 shares of the medical equipment provider’s stock after selling 844 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Zimmer Biomet were worth $311,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Chicago Partners Investment Group LLC boosted its stake in Zimmer Biomet by 3.3% during the second quarter. Chicago Partners Investment Group LLC now owns 3,865 shares of the medical equipment provider’s stock worth $376,000 after buying an additional 124 shares in the last quarter. Private Trust Co. NA lifted its holdings in shares of Zimmer Biomet by 14.6% during the 2nd quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock worth $98,000 after acquiring an additional 137 shares during the period. Brooklyn Investment Group boosted its position in shares of Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 145 shares in the last quarter. IFP Advisors Inc increased its stake in Zimmer Biomet by 8.3% in the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock valued at $178,000 after acquiring an additional 149 shares during the period. Finally, Pflug Koory LLC raised its position in Zimmer Biomet by 4.9% in the second quarter. Pflug Koory LLC now owns 3,866 shares of the medical equipment provider’s stock worth $353,000 after purchasing an additional 181 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.5%

ZBH opened at $89.50 on Thursday. The stock has a market cap of $17.74 billion, a PE ratio of 21.78, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a fifty day moving average of $97.69 and a 200-day moving average of $96.79. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $85.33 and a twelve month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the prior year, the business earned $1.74 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is currently 23.76%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by company insiders.

Analyst Ratings Changes

ZBH has been the topic of several analyst reports. Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Johnson Rice set a $112.00 price target on shares of Zimmer Biomet in a report on Wednesday, November 5th. Barclays dropped their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research note on Wednesday, November 5th. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $109.00.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.